Rational Pharmacotherapy in Cardiology

Advanced search

Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines

Full Text:


Coronary revascularization is one of the most studied types of interventions in cardiology, but there is no consensus among specialists about the indications for its implementation in patients with chronic coronary syndromes (CCS). The data of recently completed clinical trials on the role of revascularization in CCS clearly contradict the current Guidelines, emphasizing the high effectiveness of modern conservative therapy. This paper discusses the main recommendations of the most significant American and European Guidelines on myocardial revascularization, and also analyzes the appropriateness of revascularization to improve the prognosis and symptoms in chronic coronary syndromes in view of the new research data, primarily the ISCHEMIA study (NCT01471522). Its strengths and limitations are discussed in detail. The data on the expediency of revacularization in CCS, obtained after the completion of ISCHEMIA and its potential significance, as well as subgroup analyses of ISCHEMIA, including in the most important ‘problem’ subgroups (3-vessel disease, proximal LAD disease, severe ischemia on stress test, etc.) are discussed. The paper also discusses the important achievements in modern drug therapy of chronic coronary syndromes, primarily antithrombotic therapy. The data of the COMPASS study (NCT01776424) are discussed, based on which the addition of a second antithrombotic drug – rivaroxaban in a small dose (2.5 mg BID) – is recommended for patients with CCS without atrial fibrillation who have high-risk characteristics. Indications the administration of dual antithrombotic therapy to patients with CCS, comparative results of its various regimens in relation to the prevention of cardiovascular complications, the risk of bleeding and the net clinical effect are given.

About the Authors

L. L. Bershtein
Northwestern State Medical University named after I.I. Mechnikov
Russian Federation

Leonid L. Bershtein

St. Petersburg

E. V. Zbyshevskaya
Northwestern State Medical University named after I.I. Mechnikov
Russian Federation

Elizaveta V. Zbyshevskaya

St. Petersburg

V. E. Gumerova
Northwestern State Medical University named after I.I. Mechnikov
Russian Federation

Viktoria E. Gumerova

St. Petersburg


1. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541-619. DOI:10.1093/eurheartj/ehu278.

2. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI:10.1093/eurheartj/ehy394.

3. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.

4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164. DOI:10.1016/j.jacc.2012.07.013.

5. Bershtein LL, Zbyshevskaya EV, Katamadze NO, et al. ISCHEMIA is the largest ever randomized study on stable coronary heart disease. Baseline characteristics of included patients on the example of a Russian center. Kardiologiia. 2017;57(10):12-9 (In Russ.) DOI:10.18087/cardio.2017.10.10038.

6. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232-40. DOI:10.1001/jamainternmed.2013.12855.

7. Rajkumar CA, Nijjer SS, Cole GD, et al. 'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures: Lessons from DEFER and FAME-2 for End Points in the ISCHEMIA Trial. Circ Cardiovasc Qual Outcomes. 2018;11:e004665. DOI:10.1161/CIRCOUTCOMES.118.004665.

8. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379(3):250-259. DOI:10.1056/NEJMoa1803538.

9. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol. 1990 Nov 6;66(16):44G-47G. DOI:10.1016/0002-9149(90)90395-h. PMID: 2239714.

10. Hochman JS, Reynolds HR, Bangalore S, et al.; ISCHEMIA Research Group. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2019;4(3):273-86. DOI:10.1001/jamacardio.2019.0014.

11. Maron DJ, Hochman JS, Reynolds HR, et al.; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-407. DOI:10.1056/NEJMoa1915922.

12. Spertus JA, Jones PG, Maron DJ, et al.; ISCHEMIA Research Group. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020;382(15):1408-19. DOI:10.1056/NEJMoa1916370.

13. Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the Seattle angina questionnaire. Circ Cardiovasc Qual Outcomes. 2014;7(5):640-7. DOI:10.1161/CIRCOUTCOMES.114.000967.

14. Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.

15. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-35. DOI:10.1016/j.cjca.2017.06.001.

16. Cannon CP, Khan I, Klimchak AC, et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017;2(9):959-66. DOI:10.1001/jamacardio.2017.2289.

17. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-30. DOI:10.1056/NEJMoa1709118.

18. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23): 2736-47. DOI:10.1161/CIRCULATIONAHA.110.009449.

19. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. DOI:10.1016/s0140-6736(96)09457-3.

20. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.

21. Steg PG, Bhatt DL, Simon T, et al.; THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-20. DOI:10.1056/NEJMoa1908077.

22. Steg PG, Bhatt DL. Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics? Circulation. 2018;137(14):1429-31. DOI:10.1161/CIRCULATIONAHA.117.033442.

23. Leiter LA, Bhatt DL, McGuire DK, et al.; THEMIS Steering Committee and Investigators. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. J Am Coll Cardiol. 2021;77(19):2366-77. DOI:10.1016/j.jacc.2021.03.298.

24. Bainey KR, Welsh RC, Connolly SJ, et al.; COMPASS Investigators. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020;141(14):1141-1151. DOI:10.1161/CIRCULATIONAHA.119.044598.

25. Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol. 2019;73(2):121-30. DOI:10.1016/j.jacc.2018.10.048.

26. Boden WE, O'Rourke RA, Teo KK, et al.; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16. DOI:10.1056/NEJMoa070829.

27. Chatterjee S. Comparison of the ISCHEMIA Trial Population to Patients Undergoing Percutaneous Coronary Intervention in US Practice: A Cathpci National Cardiovascular Data Registry (NCDR) Research to Practice (R2P) Initiative [cited by Jun 15, 2021]. Available from:

28. Stone G. Impact of Completeness of Revascularization on Clinical Outcomes in Patients With Stable Ischemic Heart Disease Treated With an Invasive Versus Conservative Strategy: The ISCHEMIA Trial [cited by Jun 15, 2021]. Available from:

29. Weintraub WS, Hartigan PM, Mancini GBJ, et al. Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019;12(2):e005079. DOI:10.1161/CIRCOUTCOMES.118.005079.

30. Bangalore S, Maron DJ, Stone GW, Hochman JS. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2020;142(9):841-57. DOI:10.1161/CIRCULATIONAHA.120.048194.

31. Stable ischemic heart disease. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4076 (In Russ.) DOI:10.15829/1560-4071-2020-4076.

32. Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease [cited by Jun 15, 2021]. Available from:

33. Darmon A, Bhatt DL, Elbez Y, et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018;39(9):750-757a. DOI:10.1093/eurheartj/ehx658.

34. Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL. Atherosclerosis. 2018;275:262-4. DOI:10.1016/j.atherosclerosis.2018.06.821.

35. Liu H, Yu J, Chen F, Li J, Hu D. Inpatients with coronary heart disease have a high prevalence of chronic kidney disease based on estimated glomerular filtration rate (eGFR) in China. Heart Vessels. 2007;22(4):223-8. DOI:10.1007/s00380-006-0964-7.

36. Kownator S, Cambou JP, Cacoub P, et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis. 2009;102(8-9):625-31. DOI:10.1016/j.acvd.2009.05.004.

37. Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: Insights from the COMPASS Trial. Circulation. 2020;141(23):1841-54. DOI:10.1161/CIRCULATIONAHA.120.046448.


For citations:

Bershtein L.L., Zbyshevskaya E.V., Gumerova V.E. Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines. Rational Pharmacotherapy in Cardiology. 2021;17(5):761-770. (In Russ.)

Views: 303

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)